Vegfr Articles & Analysis
5 news found
“We believe that the safety and efficacy data observed in cohort A of the Phase 2 portion of the DEDUCTIVE study continue to support the development of tivozanib to serve as an attractive VEGFR TKI to use in combination with durvalumab in first line HCC patients,” said Michael Bailey, President and Chief Executive Officer of AVEO. ...
View the full release here: https://www.businesswire.com/news/home/20220105005121/en/ “Preclinical and early clinical data have demonstrated enhanced anti-tumor activity by the combination of HIF2α and VEGFR inhibition. Given tivozanib’s established excellent clinical profile, we are excited to work with AVEO to explore such opportunity,” said Zhenhai ...
Data highlighting outcomes of the subgroup of TIVO-3 patients who received tivozanib following prior axitinib therapy suggests that tivozanib, a potent and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), is more active following prior VEGFR TKI therapy than sorafenib, a multi-targeted VEGFR TKI. ...
Lenvima® (a multiple kinase inhibitor including VEGFR) with combined therapy ?Combined radiotherapy. The MSD Keytruda® and the combined therapy include free Keytruda® support to around 200 patients from MSD. ...
“With today’s FDA approval of avelumab in combination with axitinib, we can now offer patients with advanced RCC a first-line treatment option that combines a PD-L1 immunotherapy with a well-known VEGFR TKI to provide a significant reduction in the risk of disease progression or death and doubling of the response rate compared with ...